Efficiency of Nimesil in the case of chronic prostatitis/chronic pelvic pain syndrome in men

Authors

  • М. Г. Романюк ГУ «Институт урологии НАМН Украины», г. Киев
  • О. М. Корнієнко ГУ «Институт урологии НАМН Украины», г. Киев
  • П. В. Аксьонов ГУ «Институт урологии НАМН Украины», г. Киев

DOI:

https://doi.org/10.30841/2307-5090.2(57).2016.82948

Keywords:

chronic prostatitis with chronic pelvic pain syndrome, nonspecific anti-inflammatory agents, results of treatment

Abstract

The aim of the study: to study the efficacy of one of not steroid antiinflammatory drugs (NSAIDs) class sulfonamide nimesulide (Nimesil) among middle-aged men with CP/CPPS. Materials and methods. A study was conducted on a selective competitive inhibitor cycloxygenase-2 nimesulide 88 among middle-aged men with CP/CPPS. Group 1 (n=40) consisted of patients who were assigned to levofloxacin 500 mg 2 times a day. Group 2 (n=48) included men who received levofloxacin 500 mg 2 times a day and Nimesil (company Berlin-Chemie AG, Germany) по100 mg 2 times a day for 3 weeks. To obtain objective symptoms at baseline and after 3 weeks of treatment used the International scale prostatic symptoms (IPSS) and the index of the symptoms of prostatitis the National institutes of health (NIH-CPSI). Results. The mean change in total IPSS in comparison with the initial, was higher in group 2 than in group 1 (group 1 and 1.1, group 2 and 4.3; p<0.05). Significant improvement was noted in subscale urination index IPSS (group 1 and 0.7, group 2 is 3.0; p <0.05). Change of index the NIH-CPSI in group 2 was significantly more pronounced than in group 1 (group 1 3, 2-group 2 7,2; p <0,05). Significant changes were noted in the domains of urination (group 1 0.5, and group 2 1,7; p<0.05) and quality of life (group 1 1.0 for group 2 and 1.8; p<0.05) index of the NIH-CPSI. Conclusion. Nimesil (100 mg 2 times a day was well tolerated and significantly improved symptoms of CP/CPPS in men of middle age. Nimesil can be a useful drug for the treatment of CP/CPPS as a monotherapy and in combination with other drugs for empirical therapy.

Author Biographies

О. М. Корнієнко, ГУ «Институт урологии НАМН Украины», г. Киев

Корниенко Алексей Михайлович

П. В. Аксьонов, ГУ «Институт урологии НАМН Украины», г. Киев

Аксенов Павел Валерьевич

References

Krieger J.N., Nyberg L.Jr., Nickel J.C. NIH consensus definition and classification of prostatitis. JAMA 1999;282:236–7.

Strauss A.C., Dimitrakov J.D. New treatments for chronic prostatitis/chronic pelvic pain syndrome. Nat Rev Urol 2010;7:127–35.

Issa W., Roumeguere T., Bossche M.V. Chronic pelvic pain syndrome. Rev Med Brux 2013;34:29–37.

Pontari M.A., Ruggieri M.R. Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol 2004;172:839–45.

Nickel J.C. Prostatitis and related conditions, orchitis, and epididymitis. In: Wein A.J., Kavoussi L.R., Novick A.C., Partin A.W., Peters C.A., editors. Campbell-Walsh urology. 10th ed. Philadelphia: Saunders; 2012;327–71.

Pontari M., Giusto L. New developments in the diagnosis and treatment of chronic prostatitis/chronic pelvic pain syndrome. Curr Opin Urol 2013;23:565–9.

Nickel J.C., Narayan P., McKay J., Doyle C. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol 2004;171: 1594–7.

Issue

Section

For practicing physicians